155 results on '"Némati, Fariba"'
Search Results
2. Multi-omics comparison of malignant and normal uveal melanocytes reveals molecular features of uveal melanoma
3. Ferrocifen stealth LNCs and conventional chemotherapy: A promising combination against multidrug-resistant ovarian adenocarcinoma
4. Evaluation of Combined Chemotherapy and Genomic-Driven Targeted Therapy in Patient-Derived Xenografts Identifies New Therapeutic Approaches in Squamous Non-Small-Cell Lung Cancer Patients.
5. A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression
6. Improvement of the anti-proliferative activity of the peptide ERα17p in MCF-7 breast cancer cells using nanodiamonds
7. Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1–derived peptides overcomes drug resistance
8. PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers
9. FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma
10. Supplementary Data from Establishment and Characterization of a Panel of Human Uveal Melanoma Xenografts Derived from Primary and/or Metastatic Tumors
11. Supplementary Figure 1 from Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer
12. Supplementary Methods from Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer
13. Data from Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer
14. Supplementary Figure Legend from Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer
15. High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-XL inhibition against Ewing sarcoma
16. Optimization of tumor xenograft dissociation for the profiling of cell surface markers and nutrient transporters
17. High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-XL inhibition against Ewing sarcoma
18. Abstract 4031: PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer
19. Abstract LB567: Dramatic in vivo efficacy of the EZH2-inhibitor tazemetostat in PBRM1-mutated human chordoma xenograft
20. Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft
21. PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer
22. PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer
23. TIPIN depletion leads to apoptosis in breast cancer cells
24. High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC
25. Patient-derived xenografts recapitulate molecular features of human uveal melanomas
26. Multicenter Phase II Feasibility Trial of High-Dose Tamoxifen in Patients With Refractory or Relapsed Multiple Myeloma
27. PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma
28. Protein arginine methyltransferase 5: A novel therapeutic target for triple‐negative breast cancers
29. LRP8 is overexpressed in estrogen-negative breast cancers and a potential target for these tumors
30. Abstract 1718: Tumor immune gene profile before and after various targeted therapies in NSCLC PDXs
31. LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers
32. Selumetinib-based therapy in uveal melanoma patient-derived xenografts
33. The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages
34. Nanobodies against surface biomarkers enable the analysis of tumor genetic heterogeneity in uveal melanoma patient-derived xenografts
35. LRP8 is overexpressed in estrogen‐negative breast cancers and a potential target for these tumors.
36. Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating Leukocytes
37. Abstract 2087: The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma
38. Abstract 3027: Dual inhibition of PKC and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma
39. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma
40. The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
41. Abstract B164: Identification and validation of PRMT1 as a therapeutic target in breast cancer
42. Abstract A01: Ex vivo evaluation of an anti-Müllerian hormone type II receptor humanized antibody with optimized Fc effector function in ovarian cancer
43. Abstract POSTER-THER-1404:in vivosynergism between chemotherapy and the 3C23K monoclonal antibody directed against the anti-müllerian hormone type II receptor in ovarian cancer patient-derived xenografts
44. Uveal Melanoma Patient-Derived Xenografts
45. Abstract 2627: Use of xenografts for preclinical drug testing
46. Abstract 2764: The depletion of LRP5, unlike that of LRP6, promotes apoptosis in triple-negative breast cancer cells, making it an interesting therapeutic target
47. Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings
48. Targeting Bcl-2/Bcl-XL Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts
49. Abstract B233: The depletion of LRP5, unlike that of LRP6, promotes apoptosis in triple-negative breast cancer cells, making it an interesting therapeutic target.
50. Abstract LB-263: Identification of gene-expression modifications related to the tumor engraftment in patient-derived xenograft models of solid tumors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.